ONCOLYS BIOPHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 706 JPY | -0.56% |
|
+1.15% | +24.51% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +24.51% | 96.38M | |
| +1.45% | 40.51B | |
| -15.94% | 31.67B | |
| +52.66% | 24.62B | |
| -14.50% | 15.65B | |
| -14.38% | 12.07B | |
| -9.12% | 11.97B | |
| -42.56% | 11.61B | |
| +4.87% | 8.81B | |
| -4.33% | 8.5B |
- Stock Market
- Equities
- 4588 Stock
- News Oncolys BioPharma Inc.
- Oncolys Biopharma Partner Enrolls First Patient in Phase IIa Study of Aicardi-Goutières Syndrome Drug
